Category: Drug Development
Drug Development market research reports by Global Markets Direct
-
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) D ... Read More
-
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, ... Read More
-
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 ... Read More
-
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, ... Read More
-
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or ... Read More
-
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or A ... Read More
-
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.1 ... Read More
-
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides an overview of the Myelody ... Read More
-
Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Drugs In Development, 2022, provides an overview of the Parkinson's Disea ... Read More
-
Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/i ... Read More
-
20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary 20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regula ... Read More
-
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022'; C-C Chemok ... Read More
-
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospi ... Read More
-
Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline ... Read More
-
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2 ... Read More
-
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Protein Kinase C Epsilon Type - Drugs In Development, 2022'; Protein Kinase C Epsilon ... Read More
-
Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Catenin Beta 1 - Drugs In Development, 2022'; Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes c ... Read More
-
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 21 molecules. Out of which approxi ... Read More
-
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constit ... Read More
-
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molec ... Read More
-
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglan ... Read More
-
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or p ... Read More
-
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV ... Read More
-
Hepatitis A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Drugs In Development, 2022, provides an overview of the Hepatitis A (Infectious Disease) ... Read More
-
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides an overview of the Epidermolysis ... Read More
Research Assistance
